{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:01Z","timestamp":1787721661238,"version":"build-2784847793"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Survival benefit of thoracic radiotherapy (TRT) in patients with stage IV non-small cell lung cancer (NSCLC) receiving first-line chemo-immunotherapy remains uncertain. This study developed and validated an overall survival (OS) prediction model and assessed whether TRT benefit varied across risk strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with stage IV NSCLC treated with first-line chemo-immunotherapy were enrolled. A nomogram was developed using baseline clinical variables to calculate individual risk scores. Patients were classified into high- and low-risk groups according to the median nomogram-derived score. OS was compared between ICI and ICI+TRT groups in the overall cohort and risk subgroups. Treatment-by-risk interaction, 1:1 propensity score matching (PSM), treatment response, TRT pattern, BED10, and metastatic burden subgroup analyses, and safety assessments were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 514 patients, 284 without TRT were assigned to training and internal validation cohorts at a 7:3 ratio, and 84 non-TRT patients formed an external validation cohort. ECOG performance status, alkaline phosphatase, total protein, platelet-to-lymphocyte ratio, and systemic immune-inflammation index were selected as optimal prognostic factors. The nomogram showed good 1- and 2-year OS discrimination, calibration, and clinical utility. Using a median risk score of 103.1, TRT improved OS only in low-risk patients (HR 0.456, 95% CI 0.285\u20130.730;\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.0011), not high-risk patients (HR 0.914, 95% CI 0.556\u20131.503;\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.7239), with consistent findings after PSM. Treatment-by-risk interaction was significant (\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.0309). Grade 1\u20132 pneumonitis was higher with ICI+TRT than ICI alone (28.8% vs. 10.3%;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;\u00a00.001), without significant differences in severe pneumonitis or immune-related adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TRT benefit was risk-dependent, improving OS in low-risk but not high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1888208","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:51:16Z","timestamp":1787719876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-adapted use of thoracic radiotherapy in stage IV non-small cell lung cancer: a multicenter prognostic model study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaxing","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqian","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Department of Medical Oncology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.Epi-15-0578","article-title":"Global cancer incidence and mortality rates and trends--an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102853","article-title":"Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial","volume":"76","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-024-02577-5","article-title":"Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)","volume":"20","author":"Tokito","year":"2025","journal-title":"Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"14827","DOI":"10.1038\/s41598-023-40779-1","article-title":"Prediction of lung papillary adenocarcinoma-specific survival using ensemble machine learning models","volume":"13","author":"Xia","year":"2023","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1105224","article-title":"Individual risk and prognostic value prediction by machine learning for distant metastasis in pulmonary sarcomatoid carcinoma: a large cohort study based on the SEER database and the Chinese population","volume":"13","author":"Yi","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6794","article-title":"Prognostic nomogram and epidemiological analysis for lung atypical carcinoid: A SEER database and external validation study","volume":"13","author":"Yi","year":"2024","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312605","article-title":"Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis","volume":"19","author":"Yang","year":"2024","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1532343","article-title":"Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297188","article-title":"Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-15","article-title":"First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis","volume":"10","author":"Facchinetti","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241246651","article-title":"Predictive value of NLR and PLR in driver-gene-negative advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: a single institutional cohort study","volume":"23","author":"Yuan","year":"2024","journal-title":"Technol Cancer Res Treat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2192047","article-title":"Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S454638","article-title":"Machine learning for prediction of non-small cell lung cancer based on inflammatory and nutritional indicators in adults: a cross-sectional study","volume":"16","author":"Wang","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1266537","article-title":"Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers","volume":"11","author":"Zhao","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1042\/ebc20220248","article-title":"Immunologically relevant effects of radiation therapy on the tumor microenvironment","volume":"67","author":"Galassi","year":"2023","journal-title":"Essays Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13096","article-title":"Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer","volume":"64","author":"Attia","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","article-title":"Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70173","article-title":"The progression patterns and subsequent treatments of first-line immunotherapy in advanced non-small cell lung cancer: a retrospective cohort study","volume":"16","author":"He","year":"2025","journal-title":"Thorac Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-1685","article-title":"Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study","volume":"15","author":"Gao","year":"2023","journal-title":"J Thorac Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrab051","article-title":"Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy","volume":"62","author":"Saito","year":"2021","journal-title":"J Radiat Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/s1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1064227","article-title":"Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.01.012","article-title":"A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer","volume":"22","author":"Mattes","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4253\/wjge.v16.i1.5","article-title":"Nomogram to predict gas-related complications during transoral endoscopic resection of upper gastrointestinal submucosal lesions: Clinical significance","volume":"16","author":"Wen","year":"2024","journal-title":"World J Gastrointest Endosc"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:51:21Z","timestamp":1787719881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1888208"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1888208","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1888208"}}